February 19 that Johnson & Johnson, an American pharmaceutical company, announced that it had submitted its application for a single dose of coronavirus candidate vaccine to be included in the Emergency Use List (EUL) to the World Health Organization.
The data submitted by Johnson & Johnson reportedly includes intermediate efficacy and safety results from the third phase clinical trial, and the company has completed the rolling submission of clinical data to WHO.
It is reported that Johnson & Johnson submitted an application for emergency use authorization of the coronavirus vaccine to the United States in February and applied to the European Union drug regulator for a license for its vaccine use.